correction they bought over 3 days Sept.29th-30th and Oct 1st for a total of 782k and now hold over 18 million shares. !
Tricia , I am starting to see the light at the end of the tunnel lol Thanks
Been saying this for a while, buyout in the works. Takes time and with todays great news look for several big hitters to bid on ARRY before year end. AZN-ROCHE-NVS My 3 picks. The longer they wait the more expensive they will be, not to mention institutions own 98% of the float for a reason :) Be patience
Been saying this for a while, buyout in the works. Takes time and with todays great news look for several big hitters to bid on arry. AZN-ROCHE-NVS
Yes this is the correct and updated article:
In a recent filing with the SEC, Jeremy Green‘s Redmile Group, which has been consistently accumulating shares of Array Biopharma Inc (NASDAQ:ARRY) for the past seven quarters, revealed that it has yet again increased its stake in the company. Redmile now owns 17.25 million shares of Array Biopharma, which is a 12% increase from almost 15.4 million shares it disclosed owning on August 5 in a regulatory filing, and more than 30% increase from the over 13.2 million shares of the company it held at the end of June. Redmile’s present stake in Array Biopharma Inc is worth $101.25 million.
I would suggest we wait until this coming weekend (conference) to decide how we will vote . Hoping to hear some good news and partnership announcement. This will simplify our voting.
Iv been a BIG supporter of RON and ARRAY for many years, but I have to agree on his pay . BOD could get an experienced CEO for 1/2 the cost and better SHV. I believe RON has gotten to complacent with his position and have to agree its time for CHANGE !!!!!!!.
Where are all the longs ? dfcaf always had some informative info....any words ? on action. I have been lonfg the stock but , truly not pleased with shareholder value and transparency of transactions. Basically the ceo
• Loxo's collaboration with Array BioPharma continues to generate compelling and differentiated chemical matter. Loxo has used its multi-target, prioritize-by-success collaboration structure to focus on RET and FGFR.
Clinical Validation for LOXO-101 Published in Cancer Discovery
dcaf7 what's your opinion, where does arry go from here ? There pipeline is still one of the deepest out there for a sub 10.00 stock. Buyout ?
RIGHT ON the money , biotech, somebodies been buying the dip all morning, Would not be surprised if it closes green
been watching the chart and volume last 4 weeks , imo the mm's are taking out your stop losses with minimal volume, When arry explodes it will move a lot higher (% wise) than if it were trading in the 8.00 range Stay patience folks. Please listen to the last CC before you start trying to BS this board